Seeking Alpha

Pacira Announces Publication of Pivotal Study of EXPAREL as a Sciatic Nerve Block in the Popliteal Fossa for Patients After Bunionectomy

TAMPA, Fla., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (PCRX),, the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today announced ...
Healio

Ultrasound guidance for sciatic nerve blocks shown to have a 99% success rate

Please provide your email address to receive an email when new articles are posted on . VANCOUVER, British Columbia — Recent research indicates that using ultrasound guidance for the placement of ...
Nasdaq

Pacira's (PCRX) Label Expansion Study on Exparel Meets Goal

Pacira BioSciences, Inc. PCRX announced positive top-line data from a phase III study evaluating its marketed drug, Exparel, as a single-dose sciatic nerve block in the popliteal fossa for ...
Healio

Pacira receives FDA approval of expanded label for Exparel

Please provide your email address to receive an email when new articles are posted on . The expanded label includes administration as adductor canal block and sciatic nerve block in the popliteal ...
Business Insider

Pacira BioSciences Announces Positive Topline Data from Phase 3 Study of EXPAREL as a Single-dose Sciatic Nerve Block in the Popliteal Fossa for Bunionectomy

Markets Insider and Business Insider Editorial Teams were not involved in the creation of this post. Pacira Pharmaceuticals NewsMORE Related Stocks Indices Commodities Currencies Stocks ...